Free Trial

MS Launched, Bristol-Myers Squibb 7Pt Updates

PIPELINE
  • Date $MM Issuer (Priced *, Launch #
  • 11/09 $4.5B #Morgan Stanley $1.75B 3NC2 +37.5, $2.75B 11.25NC10.25 +85
  • 11/09 $Benchmark Bristol-Myers Squibb 7pt: 3NC1 +35a, 3NC1 FRN L-equiv, 5Y +40a, 7Y +50a, 10Y +60a, 20Y +70a, 30Y +90a. Last multi-tranche jumbo issue from Bristol-Myers: total $19B in 9-parts on May 7, 2019: $750M 1.5Y +20, $1B 2Y +35, $1.5B 3Y fix +45, $500M 3Y FRN L+38, $3.25B 5Y +73, $2.25B 7Y +90, $4B 10Y +105, $2B 20Y +30, $3.75B 30Y +145.
  • 11/09 $600M Entergy LA 10Y +95a, Tap 2.9% +120a
  • 11/09 $600M Consolidated Edison 40Y +155a
  • 11/09 $Benchmark Vereit +7Y +220a, 12Y +245a
  • 11/09 $Benchmark Republic Srvcs 5Y +70a, 11Y +105a
  • 11/09 $Benchmark Caterpillar 5Y +40a, (adds to $2B issued on May 12 and Jan 9)
  • 11/09 $Benchmark Westpac 15NC10, 20Y
  • 11/09 Allianz PNC 5.4Y investor call

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.